No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ENLV250117P2500
- 1.30
- 0.000.00%
15min DelayClose Jan 17 16:00 ET
0.00High0.00Low
0.00Open1.30Pre Close0 Volume0 Open Interest2.50Strike Price0.00Turnover0.00%IV-0.84%PremiumJan 17, 2025Expiry Date1.31Intrinsic Value100Multiplier-5DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.92Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Enlivex Therapeutics and BioAffinity Technologies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target
Enlivex Therapeutics Receives Regulatory Authorization From Israeli Ministry Of Health For Initiation Of Phase I Trial Evaluating Allocetra In Patients With TMJ Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients With TMJ Osteoarthritis
Enlivex Therapeutics Analyst Ratings
Elivex Therapeutics Shares Are Trading Higher After the Company Announced Interim Efficacy Data Showing Statistical Significance and Marked Improvements for Its Allocetra Trial.